Mircette

Mircette®

A proprietary oral contraceptive.

Adverse effects
Thrombophlebitis, venous thrombosis, pulmonary embolism, myocardial infarction, cerebral haemorrhage, cerebral thrombosis, hypertension, gallbladder disease, hepatic adenomas.

Mircette

Gynecology An OC that contains desogestrel/ethinyl estradiol and ethinyl estradiol. See Oral contraceptive.
References in periodicals archive ?
It's not whether the estrogen is present or absent, but [it's] the change in estrogen, and I find many patients don't do well on Mircette because of fluctuations in estrogen.
The year-over-year variance is primarily attributable to the Mircette and Novo hGH property litigation settlements.
Sales of our ParaGard IUD and Mircette oral contraceptive, each acquired in the quarter ended December 31, 2005, together with sales of our SEASONIQUE extended-cycle oral contraceptive that was launched in the quarter ended September 30, 2006, drove the increase in proprietary sales for the quarter.
63 After tax effect of: Reimbursement related to Mircette settlement charge (0.
Under the terms of the transaction Barr will acquire the exclusive rights to Organon's Mircette (Desogestrel/Ethinyl Estradiol) oral contraceptive product.
We are also working to close the proposed Mircette transaction and will continue to invest heavily in generic and proprietary R&D, positioning Barr for continued success in the future," Downey added.
Duramed Pharmaceuticals filed its application for Mircette in May 2000, and the FDA accepted the application in July 2000, initiating the patent challenge case between Bio-Technology General Corp.
Although this decision is currently being appealed, the Court ruling cleared the way for the FDA to grant Barr final approval to begin the manufacturing, selling and marketing of a generic version of Mircette.
Our generic version of Mircette, which was acquired as part of our merger with Duramed Pharmaceuticals, becomes the latest oral contraceptive in our growing franchise of female healthcare products.